Loading
This study tests a PARP inhibitor; the registry reports that it is withdrawn.
The registry lists NCT07060365 as withdrawn, last updated 2026-04-03. Enrolment is 0 actual participants. Interventions: Saruparib. Primary measures include Number of participants with treatment-emergent adverse event (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuation. The registry reason for stopping is: The study termination is based on Sponsor decision and is not related to any safety, efficacy or quality concerns. No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/